Novo Nordisk Q3 EPS $0.73 Beats $0.71 Estimate, Sales $8.58B Beat $7.91B Estimate
Portfolio Pulse from Benzinga Newsdesk
Novo Nordisk (NYSE:NVO) reported Q3 earnings of $0.73 per share, beating the analyst consensus estimate of $0.71 by 2.82%. This is a 69.77% increase from the same period last year. The company also reported quarterly sales of $8.58 billion, beating the analyst consensus estimate of $7.91 billion by 8.42%, a 38.91% increase from the same period last year.
November 02, 2023 | 7:46 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Novo Nordisk's Q3 earnings and sales exceeded estimates, indicating strong financial performance.
Novo Nordisk's Q3 earnings and sales exceeded analyst estimates, which is likely to positively impact investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 100
IMPORTANCE 100
RELEVANCE 100